A5040669754- Pneumonia and Respiratory Infections
- Nosocomial Infections in ICU
- Respiratory viral infections research
- Sepsis Diagnosis and Treatment
- Respiratory Support and Mechanisms
- Antibiotic Resistance in Bacteria
- Antibiotic Use and Resistance
- Emergency and Acute Care Studies
- Antimicrobial Resistance in Staphylococcus
- Pneumocystis jirovecii pneumonia detection and treatment
- Antibiotics Pharmacokinetics and Efficacy
- COVID-19 Clinical Research Studies
- Intensive Care Unit Cognitive Disorders
- Bacterial Identification and Susceptibility Testing
- Inhalation and Respiratory Drug Delivery
- Influenza Virus Research Studies
- Tuberculosis Research and Epidemiology
- Immune Response and Inflammation
- Airway Management and Intubation Techniques
- Long-Term Effects of COVID-19
- Mechanical Circulatory Support Devices
- Respiratory and Cough-Related Research
- Streptococcal Infections and Treatments
- Clostridium difficile and Clostridium perfringens research
- Cardiac Arrest and Resuscitation
Northwestern University
2016-2025
Lung Institute
2023
Pulmonary Associates
2005-2021
Pulmonary and Critical Care Associates
1996-2021
Shionogi (Japan)
2021
American Thoracic Society
2021
GlaxoSmithKline (Brazil)
2021
Roche (Switzerland)
2021
Merck (Germany)
2021
Polyphor (Switzerland)
2021
priate starting point for consultation by specialists.Substantial overlap exists among the patients whom these guidelines address and those discussed in recently published health care-associated pneumonia (HCAP).Pneumonia nonambulatory residents of nursing homes other long-term care facilities epidemiologically mirrors hospital-acquired should be treated according to HCAP guidelines.However, certain whose conditions are included designation better served management accordance with CAP...
Community-acquired pneumonia is a leading infectious cause of hospitalization and death among U.S. adults. Incidence estimates confirmed radiographically with the use current laboratory diagnostic tests are needed.
Incidence estimates of hospitalizations for community-acquired pneumonia among children in the United States that are based on prospective data collection limited. Updated has been confirmed radiographically and with use current laboratory diagnostic tests needed.We conducted active population-based surveillance requiring hospitalization younger than 18 years age three hospitals Memphis, Nashville, Salt Lake City. We excluded recent or severe immunosuppression. Blood respiratory specimens...
The most recent European guidelines and task force reports on hospital-acquired pneumonia (HAP) ventilator-associated (VAP) were published almost 10 years ago. Since then, further randomised clinical trials of HAP VAP have been conducted new information has become available. Studies epidemiology, diagnosis, empiric treatment, response to antibiotics or forms antibiotic administration disease prevention changed old paradigms. In addition, important differences between approaches in Europe the...
To evaluate the efficacy and safety of anti-tumor necrosis factor alpha monoclonal antibody (TNF-alpha MAb) in treatment patients with sepsis syndrome.Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial.A total 31 hospitals United States Canada.There were 994 syndrome enrolled this trial, 971 infused study drug.Patients prospectively stratified into shock or nonshock groups then randomized to receive a single infusion 15 mg/kg TNF-alpha MAb, 7.5 placebo....
The polymyxin antibiotics colistin (polymyxin E) and B became available in the 1950s thus did not undergo contemporary drug development procedures. Their clinical use has recently resurged, assuming an important role as salvage therapy for otherwise untreatable gram-negative infections. Since their reintroduction into clinic, significant confusion remains due to existence of several different conventions used describe doses polymyxins, differences formulations, outdated product information,...
Vasodilatory shock that does not respond to high-dose vasopressors is associated with high mortality. We investigated the effectiveness of angiotensin II for treatment patients this condition.We randomly assigned vasodilatory who were receiving more than 0.2 μg norepinephrine per kilogram body weight minute or equivalent dose another vasopressor receive infusions either placebo. The primary end point was a response respect mean arterial pressure at hour 3 after start infusion, defined as an...
Background. Post hoc analyses of clinical trial data suggested that linezolid may be more effective than vancomycin for treatment methicillin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia. This study prospectively assessed efficacy and safety linezolid, compared with a dose-optimized regimen, MRSA
Intravenously administered ciprofloxacin was compared with imipenem for the treatment of severe pneumonia. In this prospective, randomized, double-blind, multicenter trial, which included an intent-to-treat analysis, a total 405 patients pneumonia were enrolled. The mean APACHE II score 17.6, 79% required mechanical ventilation, and 78% had nosocomial A subgroup 205 (98 ciprofloxacin-treated 107 imipenem-treated patients) evaluable major efficacy endpoints. Patients randomized to receive...
Rationale: We recently reported two novel biomarkers for acute kidney injury (AKI), tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein 7 (IGFBP7), both related to G1 cell cycle arrest.Objectives: now validate a clinical test urinary [TIMP-2]·[IGFBP7] at high-sensitivity cutoff greater than 0.3 AKI risk stratification in diverse population critically ill patients.Methods: conducted prospective multicenter study 420 patients. The primary analysis was...
Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared efficacy, safety, and tolerability of linezolid with vancomycin in treatment nosocomial pneumonia. A total 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, 193 vancomycin, 1 g intravenously aztreonam for 7–21 days. Clinical microbiological outcomes were evaluated at test...
Although monotherapy for pneumococcal pneumonia is standard, a survival benefit of combination beta-lactam and macrolide therapy has been suggested.Initial empirical with effective antibiotic agents would have better outcome than single agent in patients bacteremic pneumonia.A review adult within the Methodist Healthcare System, Memphis, Tenn, between January 1, 1996, July 31, 2000. Empirical was defined as all received first 24 hours after presentation. On basis culture results, classified...
Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE remain associated with high clinical failure mortality rates, particularly in vulnerable patient populations. A Phase 3, multinational, open-label, randomized controlled trial (TANGO II) was conducted from 2014 to 2017 evaluate the efficacy/safety of meropenem-vaborbactam monotherapy versus best available therapy (BAT) CRE.A total 77 patients confirmed/suspected infection (bacteremia,...